J4I Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EDT
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.16
Previous CloseN/A
Volume0.00
Average Volume (3M)N/A
Market Cap
€8.97M
Enterprise Value€11.32M
Total Cash (Recent Filing)€1.72M
Total Debt (Recent Filing)€75.00K
Price to Earnings (P/E)―
Beta-2.07
Next Earnings
Jun 30, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding7,899,737,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.44
Price to Sales (P/S)0.00
P/FCF Ratio-4.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt reduces fixed financial obligations and refinancing exposure, giving Solvonis greater flexibility while it addresses operating challenges. This balance-sheet cushion may help preserve strategic options and limit the risk that financing costs accelerate pressure during continued development.
Positive Equity BaseA positive and improving equity base provides a stronger capital foundation than a balance sheet already impaired by accumulated losses. Although profitability remains weak, this position can support ongoing operations and offers more financial resilience over the next several quarters.
Cash Burn Tracks Reported LossesCash usage broadly tracking reported losses suggests the company’s weak earnings are not being compounded by a disproportionately larger operating cash drain. That alignment improves interpretability of financial performance and may make future funding needs easier to assess as operations develop.
Bears Say
Persistent UnprofitabilityPersistent operating and net losses show that Solvonis has not yet demonstrated a sustainable profit model. Continued deficits can consume its equity base, constrain investment capacity, and make future growth dependent on additional funding unless operations improve materially.
Revenue Has Become InconsistentRevenue falling effectively to zero in the two most recent annual periods indicates limited commercial consistency and weak evidence of an established revenue engine. Without dependable sales, operating leverage and margin improvement remain difficult to achieve over the medium term.
Persistent And Worsening Cash BurnOngoing negative operating cash flow means the business is not funding itself from operations, while worsening free cash flow increases its cash requirements. This can pressure the balance sheet over time and raise the need for external capital to sustain development.
Solvonis Therapeutics News
J4I FAQ
What was Solvonis Therapeutics’s price range in the past 12 months?
Solvonis Therapeutics lowest stock price was €0.01 and its highest was €0.15 in the past 12 months.
What is Solvonis Therapeutics’s market cap?
Solvonis Therapeutics’s market cap is €8.97M.
When is Solvonis Therapeutics’s upcoming earnings report date?
Solvonis Therapeutics’s upcoming earnings report date is Jun 30, 2027 which is in 241 days.
How were Solvonis Therapeutics’s earnings last quarter?
Solvonis Therapeutics released its earnings results on Sep 30, 2026. The company reported €0 earnings per share for the quarter.
Is Solvonis Therapeutics overvalued?
According to Wall Street analysts Solvonis Therapeutics’s price is currently Overvalued.
Does Solvonis Therapeutics pay dividends?
Solvonis Therapeutics does not currently pay dividends.
What is Solvonis Therapeutics’s EPS estimate?
Solvonis Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solvonis Therapeutics have?
Solvonis Therapeutics has 7,899,737,000 shares outstanding.
What happened to Solvonis Therapeutics’s price movement after its last earnings report?
Solvonis Therapeutics reported an EPS of €0 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Solvonis Therapeutics?
Currently, no hedge funds are holding shares in DE:J4I
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solvonis Therapeutics
Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatry.
Avingtrans
―
IMI plc
―
Mpac Group PLC
―
Morgan Advanced Materials
―
Smiths Group plc
―